Across TCGA pan-cancer cohorts, PSORS1C2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PSORS1C2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher PSORS1C2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSORS1C2 expression acts as an unfavorable survival marker.

READ and OV are the cancer types where PSORS1C2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.059	0.845	<.001	36	view →
OV	OS	Median	II,III,IV	0.023	0.844	<.001	36	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PSORS1C2 tumor-vs-normal RNA expression · all PSORS1C2 data types